Pharmaceutical CDMO is a deep penetration of the entire industry chain from preclinical research, clinical trials to product production, providing innovative process R&D and production services for enterprises, and replacing simple capacity output with high value-added technology output.
Pharmaceutical CDMO is customized R&D and production in the pharmaceutical field, and is an emerging R&D and production outsourcing model.
Pharmaceutical CDMO custom R & D production includes the clinical stage and the commercialization stage, generally from the clinical phase or phase II to provide domestic and foreign customers with the intermediates required for the synthesis of new drugs, and then in the listing review and approval, commercial production stage and the depth of the customer binding.
Technology development services, as the front-end extension of the industry chain of CDMO business, include the discovery and synthesis of new drug compounds, as well as various types of pre-process research and development services.
Pharmaceutical CDMO is an in-depth linkage of the entire industry chain from preclinical research, clinical trials to product production, providing innovative process R&D and production services for enterprises, and replacing simple production capacity output with high value-added technology output.
Process R&D and preparation, process optimization, registration and validation batch production as well as commercialization of custom R&D and production for medical manufacturers as well as biotech companies' products, especially innovative products, is a recently emerging service that is strongly supported by the state in order to keep the enduring power of pharmaceutical innovation.
Within the stock market, also because of the emergence of CDMO, derived from a number of related concepts of the stock, and in a period of time become a big hit. For pharmaceutical CDMO, it will be a mainstream development in the future, and as an investor, you can always keep an eye on this concept.